327 related articles for article (PubMed ID: 30535715)
1. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
[TBL] [Abstract][Full Text] [Related]
2. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
3. Nomogram for customized recurrence prediction in primary non-muscle-invasive bladder cancer based on routine blood and urine parameters.
He Y; Pan C; Zhang Y; Lv M; Yang B
BMC Urol; 2024 Mar; 24(1):67. PubMed ID: 38528549
[TBL] [Abstract][Full Text] [Related]
4. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
5. EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?
Busato Júnior WF; Almeida GL; Ribas CA; Ribas Filho JM; De Cobelli O
Clin Genitourin Cancer; 2016 Apr; 14(2):176-82. PubMed ID: 26444918
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a prognostic nomogram for patients with intravesical recurrence after radical nephroureterectomy for non-metastatic upper tract urothelial carcinoma.
Hou G; Zheng Y; Zhang L; Lai D; Wang F; Li X; Yan F; Tian J; Zhang G; Meng P; Wei D; Zhu Z; Yuan J; Hui Q; Yuan J
World J Urol; 2020 Aug; 38(8):1969-1975. PubMed ID: 31654221
[TBL] [Abstract][Full Text] [Related]
7. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
Zhang G; Steinbach D; Grimm MO; Horstmann M
World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
[TBL] [Abstract][Full Text] [Related]
8. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
9. A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients.
Yamada T; Tsuchiya K; Kato S; Kamei S; Taniguchi M; Takeuchi T; Yamamoto N; Ehara H; Deguchi T
Int J Clin Oncol; 2010 Jun; 15(3):271-9. PubMed ID: 20195678
[TBL] [Abstract][Full Text] [Related]
10. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
11. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
12. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
Nuhn P; May M; Sun M; Fritsche HM; Brookman-May S; Buchner A; Bolenz C; Moritz R; Herrmann E; Burger M; Tilki D; Trojan L; Perrotte P; Haferkamp A; Hohenfellner M; Wieland WF; Müller SC; Karakiewicz PI; Bastian PJ
Eur Urol; 2012 Jan; 61(1):58-64. PubMed ID: 21840642
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
14. External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1.
Almeida GL; Busato WF; Ribas CM; Ribas JM; De Cobelli O
Int Braz J Urol; 2016; 42(5):932-941. PubMed ID: 27509372
[TBL] [Abstract][Full Text] [Related]
15. Does Xylinas' nomogram accurately predict intravesical recurrence risk after radical nephroureterectomy for primary upper urinary tract urothelial carcinoma when applied to Asian populations?
Lai S; Wu P; Diao T; Seery S; Liu J; Hou H; Liu M; Wang J
Jpn J Clin Oncol; 2021 Mar; 51(3):469-477. PubMed ID: 32734304
[TBL] [Abstract][Full Text] [Related]
16. The Cancer of the Bladder Risk Assessment (COBRA) score for predicting cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder: External validation in a cohort of Korean patients.
Kim HS; Kwak C; Kim HH; Ku JH
Urol Oncol; 2019 Jul; 37(7):470-477. PubMed ID: 30935845
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
18. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
[TBL] [Abstract][Full Text] [Related]
19. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool.
D Andrea D; Abufaraj M; Susani M; Ristl R; Foerster B; Kimura S; Mari A; Soria F; Briganti A; Karakiewicz PI; Gust KM; Rouprêt M; Shariat SF
Urol Oncol; 2018 May; 36(5):239.e1-239.e7. PubMed ID: 29506941
[TBL] [Abstract][Full Text] [Related]
20. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
